Drug Approval | June 27, 2025
Biocon Biologics receives Health Canada approval for Yesafili
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Prucalopride Tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
Changhua site meets international regulatory standards for global medical applications
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Subscribe To Our Newsletter & Stay Updated
